In this dataset, assay interference covers hemolysis, lipemia and icteric contamination in serum or plasma samples — conditions that distort optical or chemical readings in clinical analyzers. Filings typically claim either a detection method (an optical probe or index calculation that flags a compromised sample) or a correction/reporting method (suppressing or adjusting a result once interference is detected). Almost all of these filings, 96.2% of the 52 records in scope, carry a G01N material-analysis-and-testing classification, showing the field is defined more by the measurement approach than by any single interferant.

The assignee ranking for this dataset contains 15 companies, led by a diagnostics-instrument maker with 15 families, stepping down to 6 families by fifth place and 2 by tenth. This is a short ranking rather than a top-100 list, so a new entrant with even a handful of well-targeted filings can register a meaningful position. The leader’s filings concentrate on pre-analytic optical screening rather than post-hoc result correction.

Filing activity peaked at 5 filings in 2019 and has declined since, reaching 0 in 2026 according to the published record. However, publication typically lags actual filing by around 18 months, so the last one to two years understate real activity and should not be read as the field going quiet in practice. The 2019 peak followed by decline is a genuine pattern worth watching for confirmation as more recent filings publish.